Sanofi's Tolebrutinib Regulatory Submission Update
Sanofi has recently shared important information regarding its ongoing communication with the FDA concerning the regulatory submission for tolebrutinib, aimed at treating non-relapsing secondary progressive multiple sclerosis (nrSPMS). The anticipated regulatory decision is expected to experience delays beyond the previously established target action date of December 28, 2025. In light of this new timeline, the company anticipates receiving further guidance from the FDA by the end of the first quarter of 2026.
Commitment to Patient Access
In a significant move to support patient access, Sanofi has submitted an expanded access protocol for tolebrutinib in nrSPMS. This decision emphasizes the company’s commitment to offering eligible patients access to this promising investigative therapy. Sanofi remains confident in the favorable risk-benefit profile of tolebrutinib, which is designed to address the unique challenges posed by nrSPMS.
Understanding Multiple Sclerosis and Its Challenges
Multiple sclerosis (MS) presents a complex challenge characterized by progressive neurological disability. This condition involves various biological shifts that affect clinical outcomes and treatment responses over time. Secondary progressive multiple sclerosis is particularly noteworthy as it affects individuals previously diagnosed with relapsing MS who no longer experience relapses, yet continue to suffer from disability accumulation. The pressing need for effective treatment options to combat disability accumulation in MS remains largely unmet.
The Role of Tolebrutinib in MS Treatment
Tolebrutinib is an innovative oral medication that acts as a Bruton’s tyrosine kinase inhibitor. This investigational therapy is specially engineered to penetrate the brain and target ongoing neuroinflammation, a primary factor in the progression of disability in MS. By addressing the inflammatory mechanisms that lead to neurodegeneration, tolebrutinib aims to tackle the root causes of progressive MS.
Sanofi's Vision for Neurodegenerative Diseases
Tolebrutinib is part of Sanofi's broader mission to develop groundbreaking treatments that confront the underlying triggers of neurological disorders. The company is actively focused on enhancing the lives of individuals suffering from debilitating neurological and neurodegenerative conditions, including chronic inflammatory demyelinating polyneuropathy, Alzheimer's, Parkinson’s, and age-related macular degeneration. Their commitment is underlined by a robust neurology pipeline, which includes several projects currently advancing through phase 3 studies.
About Sanofi
As a leading R&D driven, AI-powered biopharmaceutical company, Sanofi is dedicated to improving lives while fostering growth. The company leverages its in-depth understanding of the immune system to create effective medicines and vaccines that benefit millions globally. Sanofi prides itself on its innovative pipeline, aimed at addressing the urgent healthcare challenges of our time, and maintaining a resolute commitment to its core purpose: advancing the miracles of science for the betterment of communities. They are listed on both EURONEXT: SAN and NASDAQ: SNY.
Contact Information for Media and Investors
Media Relations
Sandrine Guendoul | +33 6 25 09 14 25 | sandrine.guendoul@sanofi.com
Evan Berland | +1 215 432 0234 | evan.berland@sanofi.com
Léo Le Bourhis | +33 6 75 06 43 81 | leo.lebourhis@sanofi.com
Victor Rouault | +33 6 70 93 71 40 | victor.rouault@sanofi.com
Timothy Gilbert | +1 516 521 2929 | timothy.gilbert@sanofi.com
Léa Ubaldi | +33 6 30 19 66 46 | lea.ubaldi@sanofi.com
Investor Relations
Thomas Kudsk Larsen | +44 7545 513 693 | thomas.larsen@sanofi.com
Alizé Kaisserian | +33 6 47 04 12 11 | alize.kaisserian@sanofi.com
Keita Browne | +1 781 249 1766 | keita.browne@sanofi.com
Nathalie Pham | +33 7 85 93 30 17 | nathalie.pham@sanofi.com
Thibaud Châtelet | +33 6 80 80 89 90 | thibaud.chatelet@sanofi.com
Yun Li | +33 6 84 00 90 72 | yun.li3@sanofi.com
Frequently Asked Questions
What recent updates did Sanofi provide regarding tolebrutinib?
Sanofi announced that the regulatory decision on tolebrutinib for nrSPMS will be delayed beyond the initial target date of December 28, 2025.
What is the significance of tolebrutinib in treating multiple sclerosis?
Tolebrutinib is designed to address neuroinflammation, a key element in disability progression in MS, providing a new potential treatment for patients.
How is Sanofi addressing patient access to tolebrutinib?
The company submitted an expanded access protocol to ensure eligible patients can access tolebrutinib during the investigational phase.
What are the current challenges facing multiple sclerosis treatment?
A significant challenge is the limited treatment options for addressing disability accumulation in secondary progressive MS.
What is Sanofi's overall mission in the biopharmaceutical space?
Sanofi aims to improve health outcomes through innovative research, focusing on diseases that impact the neurological and immune systems.
